DEA Hearing Signals Historic Turning Point for U.S. Cannabis Policy

Global attention in the cannabis industry has turned to Washington, D.C., as the U.S. Drug Enforcement Administration (DEA) launches a long-anticipated hearing on the potential reclassification of cannabis. Beginning June 29th and running through July 15th, the proceedings bring together experts, policymakers, and advocacy groups to present scientific, medical, and legal perspectives. Although no immediate decision is expected, the process could mark the most consequential shift in U.S. cannabis policy in more than half a century.

Currently, cannabis is classified at the federal level as a Schedule I substance, placing it alongside drugs such as heroin and LSD. This designation implies a high risk of abuse and no accepted medical use. However, this long-standing classification is now under scrutiny. The U.S. Department of Health and Human Services has recommended moving cannabis to Schedule III, a category that would formally acknowledge its medical value and recognize a lower abuse potential. DEA now has to decide.

The DEA hearing represents a critical step in evaluating this recommendation

It is important to clarify that reclassification does not equate to full legalization. Even under Schedule III, cannabis would remain regulated under federal narcotics laws. Nevertheless, the implications of such a shift would be substantial. Researchers would face fewer barriers in conducting studies, medical use frameworks would improve, and cannabis businesses could benefit from significant tax relief.

In particular, reclassification could eliminate the burden of Section 280E of the U.S. tax code, which currently prevents cannabis companies from deducting standard business expenses. This change alone has major financial implications, making the hearing closely watched by investors and publicly traded firms.

The DEA has opted for a comprehensive hearing process rather than an immediate ruling. Participants include scientists, state representatives, industry organizations, and opponents of cannabis liberalization. Following the hearings, an administrative law judge will issue a recommendation, after which the DEA will make its final determination.

As a result, a DEA decision is unlikely in the short term

While the outcome directly affects U.S. federal law, its global impact could be far-reaching. The United States remains a central hub for cannabis investment and research. A policy shift could stimulate international capital flows, accelerate scientific collaboration, and influence regulatory discussions in other regions. In Europe, particularly in Germany—now the continent’s largest cannabis market—stakeholders are closely monitoring developments.

Regardless of the final decision taken by DEA, the hearing itself signals a historic change in perspective. The formal reconsideration of cannabis’s medical value by a federal authority underscores a broader global shift. The coming weeks may prove pivotal in shaping the future of cannabis policy worldwide.

__

(Featured image by Elsa Olofsson via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in HanfJournal. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.